Is BioXcel Therapeutics Stock a Good Investment?
BioXcel Therapeutics Investment Advice | BTAI |
- Examine BioXcel Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioXcel Therapeutics' leadership team and their track record. Good management can help BioXcel Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BioXcel Therapeutics' business and its evolving consumer preferences.
- Compare BioXcel Therapeutics' performance and market position to its competitors. Analyze how BioXcel Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if BioXcel Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioXcel Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioXcel Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioXcel Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine BioXcel Therapeutics Stock
Researching BioXcel Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.04. BioXcel Therapeutics had not issued any dividends in recent years.
To determine if BioXcel Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioXcel Therapeutics' research are outlined below:
| BioXcel Therapeutics generated a negative expected return over the last 90 days | |
| BioXcel Therapeutics has high historical volatility and very poor performance | |
| BioXcel Therapeutics has some characteristics of a very speculative penny stock | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 355 K. | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioXcel Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering |
BioXcel Therapeutics Quarterly Liabilities And Stockholders Equity |
|
BioXcel Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioXcel Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioXcel Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BioXcel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioXcel Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-08-06 | 2019-06-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2019-03-07 | 2018-12-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2019-11-14 | 2019-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2019-05-07 | 2019-03-31 | -0.55 | -0.46 | 0.09 | 16 | ||
2018-05-14 | 2018-03-31 | -0.25 | -0.37 | -0.12 | 48 | ||
2022-08-09 | 2022-06-30 | -1.22 | -1.35 | -0.13 | 10 | ||
2018-08-08 | 2018-06-30 | -0.32 | -0.19 | 0.13 | 40 | ||
2022-11-10 | 2022-09-30 | -1.35 | -1.49 | -0.14 | 10 |
Know BioXcel Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioXcel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioXcel Therapeutics backward and forwards among themselves. BioXcel Therapeutics' institutional investor refers to the entity that pools money to purchase BioXcel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 99 K | Bank Of America Corp | 2024-06-30 | 73.4 K | Virtu Financial Llc | 2024-06-30 | 57.3 K | Hrt Financial Llc | 2024-06-30 | 53 K | Ubs Group Ag | 2024-06-30 | 52.5 K | Arete Wealth Advisors, Llc | 2024-06-30 | 43.5 K | Northern Trust Corp | 2024-09-30 | 40.7 K | Hennion & Walsh Asset Management Inc | 2024-09-30 | 40.1 K | Diversify Wealth Management, Llc | 2024-06-30 | 40 K | Vanguard Group Inc | 2024-09-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 440.7 K |
BioXcel Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.76 M.Market Cap |
|
BioXcel Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.43) | (2.55) | |
| Return On Capital Employed | (3.70) | (3.51) | |
| Return On Assets | (2.43) | (2.55) | |
| Return On Equity | 3.17 | 3.33 |
Determining BioXcel Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if BioXcel Therapeutics is a good buy. For example, gross profit margin measures BioXcel Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioXcel Therapeutics' profitability and make more informed investment decisions.
Evaluate BioXcel Therapeutics' management efficiency
BioXcel Therapeutics has return on total asset (ROA) of (0.6362) % which means that it has lost $0.6362 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Return On Equity is estimated to increase to 3.33, while Return On Tangible Assets are projected to decrease to (2.55). As of now, BioXcel Therapeutics' Non Current Assets Total are increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.43, while Non Currrent Assets Other are projected to decrease to under 82.7 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.94) | (1.84) | |
| Tangible Book Value Per Share | (1.94) | (1.84) | |
| Enterprise Value Over EBITDA | (0.74) | (0.77) | |
| Price Book Value Ratio | (1.52) | (1.60) | |
| Enterprise Value Multiple | (0.74) | (0.77) | |
| Price Fair Value | (1.52) | (1.60) | |
| Enterprise Value | 274.1 M | 238 M |
Evaluating the management effectiveness of BioXcel Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioXcel Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.289 |
Basic technical analysis of BioXcel Stock
As of the 26th of November, BioXcel Therapeutics shows the Standard Deviation of 6.23, risk adjusted performance of (0.01), and Mean Deviation of 4.54. BioXcel Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioXcel Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioXcel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioXcel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioXcel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioXcel Therapeutics' Outstanding Corporate Bonds
BioXcel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioXcel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioXcel bonds can be classified according to their maturity, which is the date when BioXcel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand BioXcel Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioXcel Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 4.54 | |||
| Coefficient Of Variation | (3,494) | |||
| Standard Deviation | 6.23 | |||
| Variance | 38.83 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (1.17) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 39.77 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 9.62 | |||
| Skewness | 0.6046 | |||
| Kurtosis | 2.6 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 4.54 | |||
| Coefficient Of Variation | (3,494) | |||
| Standard Deviation | 6.23 | |||
| Variance | 38.83 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (1.17) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 39.77 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 9.62 | |||
| Skewness | 0.6046 | |||
| Kurtosis | 2.6 |
Consider BioXcel Therapeutics' intraday indicators
BioXcel Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioXcel Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 102814.0 | |||
| Daily Balance Of Power | (0.80) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 0.48 | |||
| Day Typical Price | 0.47 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.04) | |||
| Relative Strength Index | 56.15 |
BioXcel Stock media impact
Far too much social signal, news, headlines, and media speculation about BioXcel Therapeutics that are available to investors today. That information is available publicly through BioXcel media outlets and privately through word of mouth or via BioXcel internal channels. However, regardless of the origin, that massive amount of BioXcel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioXcel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioXcel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioXcel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioXcel Therapeutics alpha.
BioXcel Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioXcel Therapeutics Corporate Management
| Frank Yocca | Chief Scientific Officer | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Javier Rodriguez | Chief VP | Profile | |
| Cedric Burg | VP Management | Profile | |
| Robert Scala | Vice Planning | Profile | |
| Chetan Lathia | Clinical Medicine | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between BioXcel Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.